Effects of valsartan and spironolactone on insulin-like growth factor-1 in cardiacmyocytes of spontaneously hypertensive rats

Abstract

Abstract: AIM: To study the inhibitive effects of valsartan and spironolactone on expression of insulin-like growth factor-1 in cardiacmyocytes of spontaneously hypertensive rats.METHODS: 18 SHRs were randomly divided into 3 groups (n =6 in each): valsartan group treated with 30 mg·kg^-1·d^-1 valsartan, spironolactone group treated with 20 mg·kg^-1·d^-1 spironolactone, and control group treated with placebo. All were administrated by gastric perfusion. 6WKY rats were served as control. After 13 weeks administration, the expressions of IGF-1 in cardiacmycytes were measured by immunohistochemistry and the IGF-1 concentrations in myocardium were measured by radiommunoassay.RESULTS: The expression of IGF-1 was higher in SHR group than that in the WKY group (P<0. 01). Valsartan and spironolactone inhibited the expression of IGF-1. The inhibitive effects of IGF-1 in valsartan group were more significantly higher than those in spironolactone group. Valsartan and spironolactone decreased blood pressure and left ventricular mass to body weight ratio (LVM/BW).CONCLUSION: IGF-1 may play an important role in the development of cardiac hypertrophy in SHR.Valsartan and spironolactone treatment can inhibit the expression of IGF-1 and prophylaxi myocardial hypertrophy.

Key words: hypertensive, cardiac hypertrophy, insulin-like growth factor-1, valsartan, spironolactone

CLC Number:

R972.4

DUAN Xiao-Chun, WANG Jin-Ming, WANG Fang, LI Heng, QIN Jin-Mei. Effects of valsartan and spironolactone on insulin-like growth factor-1 in cardiacmyocytes of spontaneously hypertensive rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(10): 1137-1141.

References

1 Leroith D, Werner H, Beither-Johmson D, Robers CT Jr. Molecular and cellular aspects of the insulin-like growth factor-1 receptor[J]. Endocr Rev, 1995;16(2): 143-63
2 Haddad GE, Blackwell K, Bikhazi A.Regulation of insulin-like growth factor-1 by the rennin-angiotensin system during regression of cardiar eccentric hypertrophy through angiotensin-converting enzyme inhibitor and AT1 antagonist[J]. Can J Physiol Pharmarol, 2003;81(2): 142-9
3 Pietro AM, Simone V, Iacopo B, Ilaria C, Gianluca P, Rita P, et al. Early sequence of cardiac adaptation and growth factor formation in pressure-and volume-overload hypertrophy[J]. Am J Phy siol Heart Circ Phy siol, 2000; 279(3): 976-85
4 Van EM, Vetter H,Grohe C. Angiotensin-converting enzyme inhibitor(ACE) inhibition atten-uates insulin-like growth factor-I (IGF-I) induced cardiac fibroblast proliferation[J]. Br J Pharmacol, 2000;131(8): 1592-6
5 Marijke B, Jacqueline C, Russ SP, William E, Mitch PD.Angiotensin Ⅱ stimulates gene expression of cardiac insulin-like growth factor-1 and its receptor through effects on blood pressure and food intake[J]. Hypertension, 1999;34:1053-9
6 Patrick D, Marjike B, Jie D.Angiotensin Ⅱmodulation insulinlike growth factor-1 expression in the cardiovascular system[J]. Thrend Cardiovasc Med, 1996; 6(6): 187-96
7 Linda B, Katharine EC, Wolfgang J. Increased insulin-like growth factor-1 protein in human left ventricular hypertrophy [J]. ExpMol Pathol, 1999;66(1): 53-8
8 Donohue TJ, Dworkin LD, Ma J, Lango MN, Catanese VM. Antihypertensive agents that limited ventricular hypertrophy inhibit cardiac expression of insulin-like growth factor-1[J]. J Invest Med, 1997;45(9): 584-91
9 Cohen-Solal A. Role of aldosterone in heart failure[J]. Eur Heart J, 2000; 2 (Suppl.A): A17-A20
10 Claude D, Bernard S.Molecular mechanism of myocardia remodeling: the role aldosterone[J]. J Mol Cell Cardiol, 2002; 34(12): 1577-84
11 Martin VE, Hans V, Christian G.Angiotensin-converting enzyme inhibitor (ACE) inhibition attenuates insulin-like growth factor-I(IGF-I) induced cardiac fibroblast proliferation[J]. Br J Pharmacol, 2000;131(8): 1592-6
12 Pitts B. The effects of spironolactone on morbidity and mortality in patients with sever heart failure[J]. N EnglMed, 1999;341 (10): 709-17
13 Valerie R, Christophe H, Jean-Sebastien S, Abdelkarim S, Bernard S, Claude D.Angiotensin AT1 receptor subtype as a cardiac target of Aldosterone[J]. Hypertension, 1999; 33(4): 981-6

[1]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[2]	YANG Sheng, WANG Deguo. Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
[3]	CUI Sumei, CUI Zhaoqiang. Application of β-blockers for hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 423-427.
[4]	CHENG Kuan. New progress in research and application of fenneridone [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 450-456.
[5]	XIE Mengdie, WANG Chenchen, LI Bingtao, OUYANG Changsheng, QIU Yumei, LI Hongming, TU Jun, SHANG Guangbin, TANG Xilan. Analysis on mechanism of frankincense volatile oil in prevention and treatment of cardiac hypertrophy based on in vitro cell experiment and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 241-252.
[6]	ZHENG Sanfu, GUO Weixi, LUO Jinzhong, QIN Shuiqing. Role and mechanism of platelet-derived growth factor/AKT pathway in pressure overload-induced ventricular remodeling [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 167-173.
[7]	FAN Jianfeng，FANG Yi，ZHENG Chunhua. Clinical efficacy of sacubitril valsartan in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 810-814.
[8]	GAO Yiwen, ZHANG Nan, LV Chanmei, YANG Xuanmei, YUE Guihua. Effects of Huanglianjiedu Decoction on vascular endothelial NO pathway in young spontaneously hypertensive rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 248-253.
[9]	CHEN Yan, ZHU Lijun, FANG Zhengmei, ZHU Hui, JIN Yuelong, SHEN Chong, YAO Yingshui. Association of insulin-like growth factor(IGF)-1 polymorphisms and efficacy of antihypertensive drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 171-179.
[10]	WEI Zihan,LI Dongbo，YUAN Zheng,LU Ying, YANG Guojie. Clinical trial of sacubitril/valsartan in the treatment of Pulmonary hypertension (PH) due to left heart disease (LHD) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 57-62.
[11]	CHENG Xiaolong, HU Kunmei, HU Haoran，XU Hanghang, YANG Jieren, HAN Jun. Effects of Chinese medicine Yuxia capsule on renal fibrosis in spontaneously hypertensive rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 632-639.
[12]	SHAO Junjin, LI Ya, LV Lei, WU Kaihua. Effects of dexmedetomidine and hydroxyethyl starch combined with fentanyl on brain glucose and oxygen metabolism in elderly patients with hypertensive cerebral hemorrhage after emergency surgery [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 688-693.
[13]	HU Kunmei, HU Haoran, SHEN Yuanyuan, LU Yining, YANG Jieren, HAN Jun. Effect of traditional Chinese medicine Yuxia capsule on renal fibrosis in spontaneously hypertensive rats and its relationship with TGF-β1/Smads signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 387-393.
[14]	WANG Zheng, WANG Hegui. Research progress of A-kinase-anchoring protein mediated regulation of cardiac hypertrophy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1304-1308.
[15]	ZHOU Si-gui, XU Li-peng, LU Yao, YUAN Xi, PAN Xue-diao, ZANG Lin-quan. Fenofibrate inhibits cardiac hypertrophy by up-regulation of short-chain acyl-CoA dehydrogenase [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(8): 868-873.